April S. Brown, PharmD, RPh
Recently announced changes in vaccine reimbursement under Medicare have implications for pharmacy billing processes.
Dr. Brown works in Corporate
Development for Sweetbay Clinical
Programs & Initiatives in southwest
Florida.
Pharmacists should be aware of
important changes in 2008 to the
Centers for Medicare & Medicaid
Services (CMS) policy for the reimbursement
of Part D vaccine administration
fees. Many pharmacists and other practitioners
are erroneously interpreting
announcements about these billing
changes to mean that all vaccine reimbursements
are shifting from Medicare
Part B to Part D.
Pharmacists planning for flu clinics or
those planning to incorporate pneumococcal
vaccinations into work flow
(based on an incorrect assumption that
these vaccines will be covered under
Part D beginning in 2008) will experience
disappointment and loss of revenue and
time.
What Is and Is Not Changing
Until 2006, only 4 vaccines (influenza,
pneumococcal, hepatitis B [for patients
at increased risk], and tetanus [as part of
treatment for traumatic wounds]) were
covered by Medicare under Part B. With
the establishment of Medicare Part D in
2006, however, additional vaccines
became covered under Part D. Even with
the new, expanded coverage and access
to other vaccines under Part D, however,
no legal basis for plans to reimburse
providers for the administration of these
Part D vaccines was created.
In December 2006, President Bush
signed into law the Tax Relief and Health
Care Act, which introduced provisions for
provider reimbursement of Part D vaccine
administration fees—specifically, for
such reimbursement to be under Part B
in 2007 and under Part D beginning in
2008 and thereafter.
Part B vs Part D Vaccines
To understand what this means for
pharmacists and physicians, a distinction
first must be made between Part B and
Part D vaccines. Part B vaccines include
influenza, pneumococcal, hepatitis B (for
individuals at high or intermediate risk),
and other vaccines (eg, tetanus toxoid),
when directly related to the treatment of
an injury or direct exposure to a disease
or condition. Reimbursement for the cost
of Part B vaccines and reimbursement
for their administration to the patient
have been—and will continue to be—billed and reimbursed through Medicare
Part B.
Thus, immunizers will continue to bill
Part B contractors for both the cost of a
Part B vaccine and its associated administration.
These vaccines also will continue
to be exempt from Part B deductibles
and copays.
Part D plan sponsors, beginning in
2008, will reimburse providers for the
cost of other vaccines not covered under
Parts A or B and also will reimburse
providers for administration of the vaccine—
when receiving a particular vaccine
is reasonable and necessary for the
prevention of illness. Examples of planincluded
vaccines, which will be listed on
Part D plan formularies, are extensive.
CMS Guidelines Evolving
Specific details regarding Part D–covered
vaccines, such as reimbursement
rates, cost sharing, and claims filing, are
still being developed. CMS has issued
general guidelines and options for plans
to consider, and the agency will continue
to work with plans to facilitate various
approaches.
Generally speaking, however, CMS believes
that Part D vaccines, including the
associated administration costs, should
be billed as 1 claim. CMS realizes that
situations may arise, however, where
one provider will need to dispense a vaccine
and another provider will need to
administer it. CMS recommends that
plans devise methods for preventing
and/or identifying double billing in these
situations (and alternatively, to verify
that a patient has been administered a
vaccine, if a claim was received for dispensing
a vaccine).
Unlike Part B vaccines, deductibles
and copays do apply to Part D vaccines.
Also, unlike Part B vaccines, where the
immunizer (pharmacist, physician, or
nurse) must take assignment and is
reimbursed from Medicare, it is possible
that providers of Part D vaccines may
not be reimbursed as network providers,
but rather may assist the beneficiary
in the submission of his or her
claim.
Evolving models may require collection
of the entire vaccine cost and
administration fee (as 1 fee) from the
patient and leave the patient to seek
reimbursement from his or her plan.
Providers should expect to see various
models develop and be aware of possible
plan differences.